Recombinant novel coronavirus vaccine composition

A technology of vaccine composition and coronavirus, which is applied in the field of recombinant new coronavirus vaccine composition, can solve the problems of weak immunogenicity and achieve the effect of reducing viral load and good immune protection effect

Pending Publication Date: 2021-01-15
SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Generally, when a single protein is used as an antigenic component of a vaccine, it

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant novel coronavirus vaccine composition
  • Recombinant novel coronavirus vaccine composition
  • Recombinant novel coronavirus vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0021]Example 1: Preparation of vaccine composition

[0022]In order to study the technical effects of the vaccine composition provided by the present invention, the inventors prepared the following vaccine composition preparations (0.5ml / dose), each of which contained rS protein, aluminum hydroxide adjuvant and / Or CpG 7909. The specific preparation method is as follows: first adsorb the CpG 7909 sample onto the aluminum hydroxide adjuvant, and prepare different ratios of CpG 7909 / aluminum hydroxide adjuvant (w / w) adsorption samples (the content of aluminum hydroxide adjuvant here is essentially The above is the content of aluminum); then add different concentrations of rS protein stock solution to the CpG 7909 / aluminum hydroxide adjuvant sample. After the above formulations are thoroughly mixed, if not applied immediately, store at 2-8°C. The specific ratio is shown in Table 1.

[0023]Table 1: Composition of each vaccine composition

[0024]

Example Embodiment

[0025]Example 2: Comparison of the immunological evaluation of the new coronavirus vaccine with different adjuvant combinations on the BALB / c mouse model

[0026]1. Mouse grouping and animal immunization strategy

[0027]Forty-eight SPF female BALB / c mice (6-8 weeks old) were divided into groups. Each group has 8 or 10 mice, a total of 5 groups. See Table 2 for group information. The mice were immunized according to the grouping situation in Table 2. The immunization method was intramuscular injection into the inner thigh of the mouse, and the injection volume was 50μl / dose / mouse (1 / 10 of the intended dose). Each mouse was immunized twice, and the immunization interval was 3 weeks.

[0028]Table 2: Comparison of BALB / c mice grouping in different adjuvant combination experiments

[0029]

[0030]2. Vaccine-induced antibody response detection

[0031]Two weeks after the second immunization, blood was collected from each group of mice to separate serum. Detect the IgG antibody titer against rS protein i...

Example Embodiment

[0036]Example 3: Comparison of the immunological evaluation of the new coronavirus vaccine with different dosage ratios in the BALB / c mouse model

[0037]1. Mouse grouping and animal immunization strategy

[0038]140 SPF female BALB / c mice (6-8 weeks old) were divided into groups. There are 10 animals in each group, a total of 14 groups. See Table 3 for group information. The mice were immunized according to the grouping situation in Table 3. The immunization method was intramuscular injection into the inner thigh of the mouse, and the injection volume was 50μl / dose / mouse (1 / 10 of the intended dose). Each mouse was immunized twice, and the immunization interval was 3 weeks.

[0039]Table 3: Grouping situation of BALB / c mice in the comparative dose ratio experiment

[0040]

[0041]2. Vaccine-induced antibody response detection

[0042]Two weeks after the second immunization, blood was collected from each group of mice to separate serum. Detect the IgG antibody titer against rS protein in serum by ELI...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a recombinant novel coronavirus (SARS-CoV-2) vaccine composition. The vaccine composition comprises a recombinant spike protein with an amino acid sequence shown in SEQ ID NO:1. The vaccine composition further comprises a pharmaceutically acceptable carrier, such as an aluminum adjuvant in combination with a CpG ODN adjuvant. The vaccine composition shows excellent immunogenicity in mice, and can induce an organism to generate high-titer antibody response biased to Th1 and high-level cellular immune response. Animal model experiments show that the vaccine composition can induce high-titer neutralizing antibodies and significantly reduce the viral load inside lung and turbinate tissues.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular, the invention relates to a recombinant novel coronavirus vaccine composition. Background technique [0002] COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2). As of October 20, 2020, more than 40 million people have been infected worldwide, and more than 1.1 million people have died from SARS-CoV-2 infection. The global pandemic of COVID-19 has had a huge impact on human health and economic development. Therefore, it is urgent to find a way to curb the spread of the virus. Vaccines are an effective and cost-effective way to eradicate the SARS-CoV-2 virus. According to the World Health Organization (WHO), as many as 42 different types of vaccine candidates have successfully entered clinical trials. [0003] SARS-CoV-2 belongs to subgroup B of the genus Beta and is an enveloped single-stranded positive-sense RNA virus. The virus genus also includes SARS-CoV ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/215A61P31/14A61P11/00
CPCA61K39/12A61K39/39A61P31/14A61P11/00C12N2770/20034A61K2039/55505A61K2039/55561A61K2300/00Y02A50/30
Inventor 刘海涛宋玉娇李佳黛周晨亮张玲莉刘革
Owner SHANGHAI ZERUN BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap